Accessibility Menu
SkinBioTherapeutics Plc logo

SkinBioTherapeutics Plc(LSE) SBTX

Market Cap£30.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-11%
5 Year-82%
1 Year-31%
1 Month+10%
£0.12
-0.17%
-0.00Today
SkinBioTherapeutics Plc last closing stock price
MetricPriceDate
Last closeGBX 11.502026-07-31
SkinBioTherapeutics Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.13%GBX 11.752026-07-24
1 month+9.52%GBX 10.502026-07-01
3 month+11,694.87%GBX 0.102026-05-01
Year to date-26.98%GBX 15.752025-12-31
1 year-31.34%GBX 16.752025-07-31
3 year-24.59%GBX 15.252023-08-01
5 year-82.44%GBX 65.502021-07-30
Since inception-11.09%GBX 0.132017-04-05

SkinBioTherapeutics Plc Financials at a Glance

Market Cap

£30.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£7.91M

Net Income (TTM)

-£3.03M

EPS (TTM)

-£0.00

P/E Ratio

-65.28

Dividend

£0.00

Beta (Volatility)

-0.08 (Low)

Price

£0.12

Volume

49,041

Open

£0.12

Previous Close

£0.12

Daily Range

£0.12 - £0.12

52-Week Range

£0.05 - £0.23

Estimated Earnings Date

Dec 2, 2026

SBTX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About SkinBioTherapeutics Plc

SkinBioTherapeutics Plc is a life sciences company focused on enhancing human health through innovative technologies that leverage the human microbiome. The company has developed two primary platforms: SkinBiotix, which strengthens the skin's natural barrier, and AxisBiotix, aimed at alleviating symptoms of psoriasis.

Products and Services
  • SkinBiotix: Enhances skin barrier and promotes repair
  • AxisBiotix: Targets gut health to improve skin conditions
  • Collaborations with industry leaders for microbiome formulations
Growth Outlook
  • Active partnerships with Croda Plc and the University of Manchester
  • Focus on expanding into cosmetic and pharmaceutical markets
  • Potential for significant market growth in microbiome-based products
Financial Highlights
  • Recent quarterly revenue of £2,165,948, showing growth potential
  • Current ratio of 6.14 indicates strong liquidity position
  • Net income for the latest quarter was -£794,259, reflecting ongoing investment in R&D
SkinBioTherapeutics Plc operates in the biotechnology sector, emphasizing the importance of the human microbiome in health and wellness. The company’s innovative products are designed to address significant health issues, particularly in dermatology and gut health. With a strong focus on research and development, SkinBioTherapeutics is well-positioned to capitalize on the growing demand for microbiome-related solutions in various industries. The recent financial performance indicates a commitment to growth, despite current net losses, as the company invests heavily in its technological advancements and partnerships. The liquidity ratios suggest a robust financial foundation, allowing for continued exploration and development of its product offerings.
AI Generated • Jul 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

41

CEO

Stuart John Ashman

Website

www.skinbiotherapeutics.com

Headquarters

Newcastle upon Tyne, TY NE4 5TF, GB

SBTX Financials

Key Financial Metrics (TTM)

Gross Margin

56.51%

Operating Margin

-20.95%

Net Income Margin

-8.73%

Return on Equity

-5.25%

Return on Capital

-7.94%

Return on Assets

-4.75%

Earnings Yield

-1.53%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£30.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

259.17M

Volume

49.04K

Avg. Volume

494.79K

Financials (TTM)

Gross Profit

£4.41M

Operating Income

-£3.65M

EBITDA

-£2.38M

Operating Cash Flow

-£4.23M

Capital Expenditure

-£41.09K

Free Cash Flow

-£4.27M

Cash & ST Invst.

£3.12M

Total Debt

£939.17K

SkinBioTherapeutics Plc Performance Analysis

SkinBioTherapeutics Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30GBP 74,761N/A
20232023-06-30GBP 132,05776.6%
20242024-06-30GBP 1,208,669815.3%
20252025-06-30GBP 4,638,147283.7%
SkinBioTherapeutics Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30934.0%
Q22024-12-3143.1%
Q42025-06-3094.1%
Q22025-12-31-29.3%
SkinBioTherapeutics Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30GBP -0.02N/A
20232023-06-30GBP -0.02-3.4%
20242024-06-30GBP -0.02-10.5%
20252025-06-30GBP -0.00-79.9%
SkinBioTherapeutics Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-5.3%
Q22024-12-3141.8%
Q42025-06-30128.3%
Q22025-12-31-338.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2025YOY CHG

Revenue

£2.17M

+1932.3%

Gross Profit

£1.13M

+1550.3%

Gross Margin

51.98%

N/A

Market Cap

£30.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£742.74K

N/A

Employees

41

N/A

Net Income

-£794.26K

+40.5%

EBITDA

-£757.08K

+44.4%

Quarterly Fundamentals

Name
Q2 2025YOY CHG

Total Cash

£3.12M

+10.0%

Total Debt

£939.17K

+867.7%

Accounts Receivable

£757.91K

+360.6%

Inventory

£925.20K

+1870.7%

Long Term Debt

£842.67K

+1311.8%

Short Term Debt

£96.50K

+29.1%

Return on Assets

-4.75%

N/A

Return on Invested Capital

-12.42%

N/A

Free Cash Flow

-£1.55M

-12.4%

Operating Cash Flow

-£1.53M

-12.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SAR.LSareum Holdings plc
£0.22+3.81%
HEMO.LHemogenyx Pharmaceuticals Plc
£6.15-2.77%
IMM.LImmuPharma PLC
£0.04+4.86%
POLB.LPoolbeg Pharma PLC
£0.06+1.52%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.13+0.11%
NVDANvidia
$195.04+0.03%
MSFTMicrosoft
$451.10+0.16%
NOKNokia
$9.09+0.08%

Questions About SBTX

What is the current price of SkinBioTherapeutics Plc?

SkinBioTherapeutics Plc is trading at £0.12 per share.

What is the 52-week range for SkinBioTherapeutics Plc?

Over the past 52 weeks, SkinBioTherapeutics Plc has traded between £0.05 and £0.23.

How much debt does SkinBioTherapeutics Plc have?

As of the most recent reporting period, SkinBioTherapeutics Plc reported total debt of £993.47K.

How much cash does SkinBioTherapeutics Plc have on hand?

SkinBioTherapeutics Plc reported £4.78M in cash and cash equivalents in its most recent financial results.

What is SkinBioTherapeutics Plc’s dividend yield?

SkinBioTherapeutics Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services